NCT01942265View on ClinicalTrials.gov

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

980

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Influenza
Interventions
DRUG

AS03

Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.

DRUG

MF59

Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.

BIOLOGICAL

Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013

Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.

Trial Locations (5)

21201-1509

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

37232-0011

Vanderbilt University Medical Center - Infectious Diseases, Nashville

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

98101-1466

Group Health Research Institute - Seattle - Vaccines and Infectious Diseases, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01942265 - H7N9 Mix and Match With AS03 and MF59 in Healthy Adults | Biotech Hunter | Biotech Hunter